Addex Therapeutics (ADXN) Capital Expenditures (2019 - 2024)

Addex Therapeutics has disclosed Capital Expenditures across 6 years of filings, most recently posting $1.5 billion for Q4 2024.

• Capital Expenditures for Q4 2024 came in at $1.5 billion, down 77.13% year-over-year; the trailing twelve-month figure through Dec 2024 was $1.5 billion (up 2017.52% YoY), and the FY2024 annual result was $1453.2, down 81.16% from the prior year.
• Capital Expenditures came in at $1.5 billion for Q4 2024 at Addex Therapeutics, down from $6.4 billion in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $6.4 billion in Q4 2023 to a low of -$5.5 billion in Q2 2023.
• The 5-year median for Capital Expenditures is -$1818.8 (2021), against an average of $101.7 million.
• Peak annual rise in Capital Expenditures reached 527315128.25% in 2023, while the deepest fall reached 127812814.85% in 2023.
• Addex Therapeutics' Capital Expenditures stood at $78252.8 in 2020, then plunged by 46.49% to $41874.8 in 2021, then plunged by 97.12% to $1205.1 in 2022, then surged by 527315128.25% to $6.4 billion in 2023, then slumped by 77.13% to $1.5 billion in 2024.
• The last three Capital Expenditures figures came in at $1.5 billion (Q4 2024), $6.4 billion (Q4 2023), and -$767.6 million (Q3 2023), per Business Quant data.